Iznardo, H, Puig, L. Beyond plaque psoriasis - pathogenesis and treatment of other psoriasis phenotypes. CURRENT OPINION IN RHEUMATOLOGY. 2022; 34(4)DOI:10.1097/BOR.0000000000000882. PMID:35699337. IF:5.100(Q2/3D).

Serra-Baldrich, E, Santamaria-Babi, LF, Silvestre, JF. Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis. Actas Dermo-Sifiliograficas. 2022; 113(7)DOI:10.1016/j.ad.2021.12.014. PMID:35842249. IF:(Q/D).

Chabra, S, Gill, BJ, Gallo, G, Zhu, DT, Pitou, C, Payne, CD, Accioly, A, Puig, L. Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials. ADVANCES IN THERAPY. 2022; 39(6)DOI:10.1007/s12325-022-02126-0. PMID:35449322. IF:3.800(Q2/4D).

Medina-Catalan, D, Riera, P, Pages-Puigdemont, N, Masip, M, Lopez-Ferrer, A, Vilarrasa, E, Puig, L. A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence. International Journal of Clinical Pharmacy. 2022; 44(3)DOI:10.1007/s11096-022-01400-z. PMID:35380392. IF:2.400(Q3/8D).

de Bruin-Weller, MS, Serra-Baldrich, E, Barbarot, S, Grond, S, Schuster, C, Petto, H, Capron, JP, Raibouaa, A, Werfel, T. Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis. Dermatology and Therapy. 2022; 12(6)DOI:10.1007/s13555-022-00734-w. PMID:35543919. IF:3.400(Q2/3D).

Sanz, C, Nomdedeu, M, Pereira, A, Sauleda, S, Alonso, R, Bes, M, Brillembourg, H, Garcia-Vidal, C, Millan, A, Martinez-Llonch, N, Piron, M, Puerta-Alcalde, P, Puig, L, Rico, V, Soriano, A. Efficacy of early transfusion of convalescent plasma with high-titer SARS-CoV-2 neutralizing antibodies in hospitalized patients with COVID-19. TRANSFUSION. 2022; 62(5)DOI:10.1111/trf.16863. PMID:35338710. IF:2.900(Q3/7D).

Puig, L, Costanzo, A, Munoz-Elias, EJ, Jazra, M, Wegner, S, Paul, CF, Conrad, C. The biological basis of disease recurrence in psoriasis: a historical perspective and current models. BRITISH JOURNAL OF DERMATOLOGY. 2022; 186(5)DOI:10.1111/bjd.20963. PMID:34939663. IF:10.300(Q1/1D).

Zozaya, N, Villoro, R, Abdalla, F, Alfonso Zamora, S, Balea Filgueiras, J, Carrascosa Carrillo, JM, Delgado Sanchez, O, Dolz Sinisterra, F, Garcia-Ruiz, A, Herranz Pinto, P, Manfredi, A, Martinez Olmos, J, Morales De los Rios Luna, P, Puig Sanz, L, Ros, S, Hildago-Vega, A. Unmet Needs in the Management of Moderate-to-Severe Psoriasis in Spain: A Multidimensional Evaluation. ACTA DERMATO-VENEREOLOGICA. 2022; 102DOI:10.2340/actadv.v102.583. PMID:35312022. IF:3.600(Q1/3D).

Canal-Garcia, E, Bosch-Amate, X, Belinchon, I, Puig, L. Nail Psoriasis. Actas Dermo-Sifiliograficas. 2022; 113(5)DOI:10.1016/j.ad.2022.01.006. PMID:35697407. IF:(Q/D).

Medrano, RM, Estebaranz, JLL, Sanmartin-Jimenez, O, Garces, JR, Rodriguez-Prieto, MA, Vilarrasa-Rull, E, De Eusebio-Murillo, E, Escutia-Munoz, B, Florez-Menendez, A, Artola-Igarza, JL, Alfaro-Rubio, A, Redondo, P, Delgado-Jimenez, Y, Sanchez-Schmidt, JM, Allende-Markixana, I, Alonso-Pacheco, ML, Garcia-Bracamonte, B, De la Cueva-Dobao, P, Navarro-Tejedor, R, Ciudad-Blanco, C, Carnero-Gonzalez, L, Vazquez-Veiga, H, Cano-Martinez, N, Ruiz-Salas, V, Sanchez-Sambucety, P, Botella-Estrada, R, Gonzalez-Sixto, B, Martorell-Calatayud, A, Gil, P, Morales-Gordillo, V, Toll-Abello, A, Ocerin-Guerra, I, Mayor-Arenal, M, Suarez-Fernandez, R, Sainz-Gaspar, L, Descalzo, MA, Garcia-Doval, I. Risk of a Second Skin Cancer in a Cohort of Patients With Nonmelanoma Skin Cancer - Basal Cell Carcinoma or Squamous Cell Carcinoma - Treated With Mohs Micrographic Surgery: A National Prospective Cohort Study. Actas Dermo-Sifiliograficas. 2022; 113(5)DOI:10.1016/j.ad.2022.01.035. PMID:. IF:(Q/D).

Blauvelt, A, Tsai, TF, Langley, RG, Miller, M, Shen, YK, You, Y, Yang, YW, Papp, KA, Puig, L. Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2022; 86(4)DOI:10.1016/j.jaad.2021.11.004. PMID:34798201. IF:13.800(Q1/1D).

Vidal, S, Puig, L, Carrascosa-Carrillo, JM, Gonzalez-Cantero, A, Ruiz-Carrascosa, JC, Velasco-Pastor, AM. From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment (vol 22, 6740, 2021). INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(5)DOI:10.3390/ijms23052649. PMID:35270045. IF:5.600(Q1/3D).

Bes, M, Costafreda, MI, Riveiro-Barciela, M, Piron, M, Rico, A, Quer, J, Puig, L, Sauleda, S. Effect of Hepatitis E Virus RNA Universal Blood Donor Screening, Catalonia, Spain, 2017-2020. EMERGING INFECTIOUS DISEASES. 2022; 28(1)DOI:10.3201/eid2801.211466. PMID:34932460. IF:11.800(Q1/1D).

Gimenez-Arnau, A, Bartra, J, Ferrer, M, Jauregui, I, Borbujo, J, Figueras, I, Munoz-Bellido, F, Pedraz, J, Serra-Baldrich, E, Tejedor-Alonso, M, Velasco, M, Terradas, P, Labrador, M. A Specialized Therapeutic Approach to Chronic Urticaria Refractory to H1-Antihistamines Improves Disease Burden: The Spanish AWARE Experience. JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY. 2022; 32(3)DOI:10.18176/jiaci.0661. PMID:33349612. IF:7.200(Q1/2D).

Gisondi P., Simon D., Alarcon I., Pournara E., Puig L.. Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients receiving secukinumab: a literature review. JOURNAL OF DERMATOLOGICAL TREATMENT. 2023; 34(1)DOI:10.1080/09546634.2023.2167487. PMID:36625506. IF:2.900(Q2/4D).

Mateu-Arrom, L, Rusinol, L, Puig, L. Reddish and edematous nodules in an immunosuppressed patient. INTERNATIONAL JOURNAL OF DERMATOLOGY. 2023; 62(7)DOI:10.1111/ijd.16512. PMID:36371702. IF:3.500(Q1/3D).

Rusinol, L, Carmona-Rocha, E, Spertino, J. Bullous eruption in a pluripathological patient. INTERNATIONAL JOURNAL OF DERMATOLOGY. 2023; 62(5)DOI:10.1111/ijd.16590. PMID:36683133. IF:3.500(Q1/3D).

Gely C., Gordillo J., Bertoletti F., González-Muñoza C., López A., García-Planella E.. Perception of the need for dietary advice and dietary modifications in inflammatory bowel disease patients. Gastroenterologia y Hepatologia. 2023; 46(5)DOI:10.1016/j.gastrohep.2022.10.005. PMID:36243252. IF:2.200(Q3/6D).

Puig L., Choon S.E., Gottlieb A.B., Marrakchi S., Prinz J.C., Romiti R., Tada Y., von Bredow D., Gooderham M.. Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(4)DOI:10.1111/jdv.18851. PMID:36606566. IF:8.500(Q1/1D).

Docampo-Simon, A, Sanchez-Pujol, MJ, Pastor-Nieto, MA, Gimenez-Arnau, A, Rodriguez-Serna, M, Serra-Baldrich, E, Miquel, J, Sanchez-Perez, J, Sanz-Sanchez, T, Zaragoza-Ninet, V, Sanchez-Pedreno, P, Carrascosa, JM, Gatica-Ortega, ME, Fernandez-Redondo, V, Cordoba-Guijarro, S, Gonzalez-Perez, R, Silvestre, JF. Patch Testing in Patients With Severe Atopic Dermatitis Treated With Dupilumab: A Multicentric Approach in Spain. Dermatitis. 2023; 34(4)DOI:10.1089/derm.2022.0023. PMID:37001174. IF:4.000(Q1/2D).

Sans-de San Nicolàs L., Figueras-Nart I., García-Jiménez I., Bonfill-Ortí M., Guilabert A., Curto-Barredo L., Bertolín-Colilla M., Ferran M., Serra-Baldrich E., Pujol R.M., Santamaria-Babí L.F.. Allergen sensitization stratifies IL-31 production by memory T cells in atopic dermatitis patients. Frontiers in Immunology. 2023; 14DOI:10.3389/fimmu.2023.1124018. PMID:36993985. IF:5.700(Q1/3D).

Lynde, C, Riedl, E, Maul, JT, Torres, T, Pinter, A, Fabbrocini, G, Daniele, F, Brnabic, A, Reed, C, Wilhelm, S, Holzkamper, T, Schuster, C, Puig, L. Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting. ADVANCES IN THERAPY. 2023; 40(3)DOI:10.1007/s12325-022-02379-9. PMID:36515803. IF:3.400(Q2/3D).

Rivera-Diaz, R, Dauden, E, Carrascosa, JM, de la Cueva, P, Puig, L. Generalized Pustular Psoriasis: A Review on Clinical Characteristics, Diagnosis, and Treatment. Dermatology and Therapy. 2023; 13(3)DOI:10.1007/s13555-022-00881-0. PMID:36635445. IF:3.500(Q1/3D).

Castillo-Regalado E., Ríos R., Aràjol C., Gely C., Márquez L., Calafat M., González-Muñoza C., Cañete F., Mesonero F., Guardiola J., Garcia-Planella E., Mañosa M., Domènech E.. Clinical and endoscopic outcomes of patients with colonic Crohn's disease treated with 5-aminosalicylates as monotherapy. Gastroenterologia y Hepatologia. 2023; 46(3)DOI:10.1016/j.gastrohep.2022.09.003. PMID:36179946. IF:2.200(Q3/6D).

Rusinol, L, Puig, L. Tyk2 Targeting in Immune-Mediated Inflammatory Diseases. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2023; 24(4)DOI:10.3390/ijms24043391. PMID:36834806. IF:4.900(Q1/3D).

Iznardo, H, Roe, E, Serra-Baldrich, E, Puig, L. Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis. Pharmaceutics. 2023; 15(2)DOI:10.3390/pharmaceutics15020385. PMID:36839707. IF:4.900(Q1/2D).

Tous-Romero, F, Gimenez-Arnau, AM, Sanz-Sanchez, T, Perez, RG, Carrascosa-Carrillo, JM, Zaragoza-Ninet, V, Cordoba-Guijarro, S, Gatica-Ortega, ME, Miquel-Miquel, J, Borrego-Hernando, L, Ruiz-Gonzalez, I, Serra-Baldrich, E, Silvester-Salvador, JF, Mercader-Garcia, P, Sanchez-Perez, J, Rodriguez-Serna, M, Pastor-Nieto, A, Hervella-Garcia, M, Garcia-Doval, I, Ortiz-de Frutos, FJ. Allergic contact dermatitis to alkyl glucosides: Epidemiological situation in Spain. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(3)DOI:10.1111/jdv.18595. PMID:36153692. IF:8.500(Q1/1D).

Gonzalez-Cao, M, Puertolas, T, Martinez-Vila, C, Carrera, C, Seral, CM, Rodriguez-Jimenez, P, Sequero, S, Cerezuela-Fuentes, P, Ochoa, RF, Munoz, E, Basa, MA, Martin-Liberal, J, Soria, A, Moreno, JFR, Marquez-Rodas, I, Criado, PL, Manzano, JL, Lopez-Castro, R, De Miguel, PA, Villalobos, L, Algarra, SM, Gonzalez-Barrallo, I, Boada, A, Castano, AG, Puig, S, Crespo, G, Fra, PL, Zamora, CA, Rodriguez, MF, Valles, L, Drozdowskyj, A, Gardeazabal, J, Fernandez-Morales, LA, Rodrigo, A, Cruz, R, Yelamos, O, Rubio, B, Mujica, K, Provencio, M, Berrocal, A. SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry. Clinical & Translational Oncology. 2023; 25(3)DOI:10.1007/s12094-022-02985-7. PMID:36566266. IF:2.800(Q2/5D).

Koren J., Lambert, JLW, Thomsen S.F., McAteer H., Fabbrocini G., Corazza V., Jullien D., Augustin M., Warren R.B., de Rie M.A., Lazaridou E., Puig L., Guillevin L., Grosser M., Boehncke, WH. Elevating the Standard of Care for Patients with Psoriasis: 'Calls to Action' from Epicensus, a Multistakeholder Pan-European Initiative. Dermatology and Therapy. 2023; 13(1)DOI:10.1007/s13555-022-00846-3. PMID:36484915. IF:3.500(Q1/3D).

Hernández Fernández C.P., Borrego L., Mercader García P., Giménez Arnau A.M., Sánchez Pérez J., Silvestre Salvador J.F., González Pérez R., Sanz Sánchez T., Sánchez Gilo A., Melé Ninot G., Zaragoza Ninet V., Miquel Miquel F.J., Carrascosa Carrillo J.M., Córdoba Guijarro S., Gatica Ortega M.E., Ruiz González I., Serra Baldrich E., Tous Romero F., Rodríguez Serna M., Pastor Nieto M.A., Pérez Feal P., Hervella Garcés M., de Vega Martínez M., García Doval I.. Sensitization to isothiazolinones in the Spanish Contact Dermatitis Registry (REIDAC): 2019–2021 epidemiological situation. CONTACT DERMATITIS. 2023; 88(3)DOI:10.1111/cod.14251. PMID:36403138. IF:4.800(Q1/2D).

Yélamos O., Andersen D., Pont M., Iglesias P., Potrony M., Domínguez M., Herrero A., Alejo B., Mateu J., Røpke M., Danneskiold-Samsøe N.B., Malvehy J., Guy R.H., Brix S., Puig S.. Development and validation of a minimally invasive and image-guided tape stripping method to sample atopic skin in children. CLINICAL AND EXPERIMENTAL DERMATOLOGY. 2023; 48(2)DOI:10.1093/ced/llac040. PMID:36730521. IF:3.700(Q1/2D).

Puig L.. Psoriasis treatment does not impair the immunogenicity of ChAOx1-S[recombinant] COVID-19 vaccination. BRITISH JOURNAL OF DERMATOLOGY. 2023; 188(2)DOI:10.1093/bjd/ljac081. PMID:36763894. IF:11.000(Q1/1D).

Egeberg A., Merola J.F., Schäkel K., Puig L., Mahar P.D., Wang I.Y., Pavo I., Schuster C., Griffiths C.E.M.. Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes. Frontiers in Medicine. 2023; 9DOI:10.3389/fmed.2022.1092688. PMID:36777159. IF:3.100(Q1/2D).

Maravilla-Herrera P., Merino M., Alfonso Zamora S., Balea Filgueiras J., Carrascosa Carrillo J.M., Delgado Sánchez O., Dolz Sinisterra F., García-Ruiz A., Herranz Pinto P., Manfredi A., Martínez Olmos J., Morales de los Ríos Luna P., Puig L., Ros S., Hidalgo-Vega Á.. The social value of a PASI 90 or PASI 100 response in patients with moderate-to-severe plaque psoriasis in Spain. Frontiers in Public Health. 2023; 11DOI:10.3389/fpubh.2023.1000776. PMID:36778548. IF:3.000(Q2/3D).

Ryan C., Puig L., Zema C., Thompson E.H.Z., Yang M., Wu E., Bensimon A., Huang X., Joshi A.D., Elewski B.. The impact of achieving and maintaining near-complete or complete skin clearance on patient quality of life in moderate-to-severe psoriasis. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2023; 88(1)DOI:10.1016/j.jaad.2021.12.032. PMID:34954285. IF:12.800(Q1/1D).

Chicharro, P, Llamas-Velasco, M, Armesto, S, Acosta, EH, Vidal, D, Vilarrasa, E, Rivera-Diaz, R, De-la-Cueva, P, Martorell-Calatayud, A, Ballesca, F, Belinchon, I, Carretero, G, Rodriguez, L, Romero-Mate, A, Pujol-Montcusi, J, Salgado, L, Sahuquillo-Torralba, A, Coto-Segura, P, Rodriguez, OB, Feltes, R, Riera-Monroig, J, Dauden, E. Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients. Dermatologic Therapy. 2022; 35(12)DOI:10.1111/dth.15929. PMID:36223184. IF:3.600(Q1/3D).

Rusinol, L, Camina-Conforto, G, Puig, L. Biologic treatment of psoriasis in oncologic patients. EXPERT OPINION ON BIOLOGICAL THERAPY. 2022; 22(12)DOI:10.1080/14712598.2022.2152322. PMID:36422998. IF:4.600(Q2/3D).

Lopez-Ferrer, A, Vilarrasa, E, Armesto, S, Santos-Juanes, J, Galache, C, Carretero, G, Sahuquillo, A, Salgado-Boquete, L, del Alcazar, E, Gonzalez-Cantero, A, Martorell, A, Rivera-Diaz, R, Mitxelena-Ezeiza, J, Mateu, A, Belinchon, I, Llamas-Velasco, M, Riera-Monroig, J, Lazaro, A, Lopez-Estebaranz, JL, Gich, I, Puig, L. Drug survival of adalimumab biosimilars in real-world treatment of psoriasis: A Spanish multicenter study. Dermatologic Therapy. 2022; 35(11)DOI:10.1111/dth.15831. PMID:36109488. IF:3.600(Q1/3D).

Reolid, A, Armesto, S, Sahuquillo-Torralba, A, Torres, T, Feltes, R, Vilarrasa, E, Belincho, I, de la Cueva, P, Rodriguez, L, Romero-Mate, A, Vidal, D, Coto-Segura, P, Herrera-Acosta, E, Riera-Monroig, J, Salgado, L, Llamas-Velasco, M, Dauden, E. Secukinumab is effective in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2022; 87(3)DOI:10.1016/j.jaad.2022.05.047. PMID:35640798. IF:13.800(Q1/1D).

Piron, M, Jane, M, Ciruela, P, Basile, L, Martinez, A, Puig, L, Bes, M, Sauleda, S. SARS-CoV-2 seroprevalence in blood donors before and after the first wave in Catalonia (Spain). Blood Transfusion. 2022; 20(5)DOI:10.2450/2022.0232-21. PMID:35175189. IF:3.700(Q2/4D).

Lopez-Ferrer, A, Laiz, A, Puig, L. Psoriatic arthritis. MEDICINA CLINICA. 2022; 159(1)DOI:10.1016/j.medcli.2022.01.024. PMID:35525675. IF:3.900(Q2/4D).

Carrascosa, JM, Puig, L, Romero, IB, Salgado-Boquete, L, del Alcazar, E, Lencina, JJA, Moreno, D, de la Cueva, P. [Translated article] Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on the Treatment of Psoriasis With Biologic Agents: Part 2-Management of Special Populations, Patients With Comorbid Conditions, and Risk. Actas Dermo-Sifiliograficas. 2022; 113(6)DOI:10.1016/j.ad.2022.01.024. PMID:35748004. IF:(Q/D).

Tubau C., Amat-Samaranch V., Flores-Climente V.. Erythematous Facial Plaques With an Unfavorable Course. Actas Dermo-Sifiliograficas. 2022; 113(6)DOI:10.1016/j.ad.2021.01.013. PMID:. IF:(Q/D).

Thyssen J.P., Schuttelaar M.L.A., Alfonso J.H., Andersen K.E., Angelova-Fischer I., Arents B.W.M., Bauer A., Brans R., Cannavo A., Christoffers W.A., Crépy M.-N., Elsner P., Fartasch M., Filon F.L., Giménez-Arnau A.M., Gonçalo M., Guzmán-Perera M.G., Hamann C.R., Hoetzenecker W., Johansen J.D., John S.M., Kunkeler A.C.M., Hadzavdic S.L., Molin S., Nixon R., Oosterhaven J.A.F., Rustemeyer T., Serra-Baldrich E., Shah M., Simon D., Skudlik C., Spiewak R., Valiukeviciene S., Voorberg A.N., Weisshaar E., Agner T.. Guidelines for diagnosis, prevention, and treatment of hand eczema. CONTACT DERMATITIS. 2022; 86(5)DOI:10.1111/cod.14035. PMID:34971008. IF:5.500(Q1/1D).

Pereyra-Rodriguez J.-J., Herranz P., Figuras-Nart I., Perez B., Elosua M., Munera-Campos M., Melgosa-Ramos J., Zaragoza Ninet V., Silvestre J.F., Campos-Domínguez M., Guilabert A., Miquel J., Alcantara-Luna S., De La Cueva P., Serra-Baldrich E., Armario-Hita J.C.. Upadacitinib for the Treatment of Atopic Dermatitis in a Spanish Cohort - Real Life: Fifty-Two-Week Follow-up Results. Dermatitis. 2022; 33(6)DOI:10.1097/DER.0000000000000958. PMID:36125777. IF:5.200(Q1/2D).

Richarz N.A., Boada A., Jaka A., Bassas J., Ferrándiz C., Carrascosa J.M., Yélamos O.. Challenges for New Adopters in Pre-Surgical Margin Assessment by Handheld Reflectance Confocal Microscope of Basal Cell Carcinoma; A Prospective Single-center Study. Dermatology Practical & Conceptual. 2022; 12(4)DOI:10.5826/dpc.1204a162. PMID:36534521. IF:2.800(Q2/4D).

Tubau C., Rusiñol L., Sánchez-Rodríguez G., Iznardo H., Amat-Samaranch V., Yélamos O.. Five Synchronous Melanomas: Role of Dermoscopy as a Triage Tool to Manage Melanoma During the COVID-19 Pandemic. Dermatology Practical & Conceptual. 2022; 12(4)DOI:10.5826/dpc.1204a209. PMID:36534517. IF:2.800(Q2/4D).

Reymundo A., Vilarrasa E., Baniandrés O., Rodríguez-Fernández-Freire L., Feltes R., Llamas-Velasco M., Daudén E.. Effectiveness and safety profile of secukinumab for the treatment of patients with generalized pustular psoriasis in daily practice. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(10)DOI:10.1111/jdv.18317. PMID:35689497. IF:9.200(Q1/1D).

Escalé-Besa A., Fuster-Casanovas A., Börve A., Yélamos O., Fustà-Novell X., Rafat M.E., Marin-Gomez F.X., Vidal-Alaball J.. Using Artificial Intelligence as a Diagnostic Decision Support Tool in Skin Disease: Protocol for an Observational Prospective Cohort Study. Jmir Research Protocols. 2022; 11(8)DOI:10.2196/37531. PMID:. IF:(Q/D).

Bechman K., Cook E.S., Dand N., Yiu Z.Z.N., Tsakok T., Meynell F., Coker B., Vincent A., Bachelez H., Barbosa I., Brown M.A., Capon F., Contreras C.R., De La Cruz C., Meglio P.D., Gisondi P., Jullien D., Kelly J., Lambert J., Lancelot C., Langan S.M., Mason K.J., McAteer H., Moorhead L., Naldi L., Norton S., Puig L., Spuls P.I., Torres T., Urmston D., Vesty A., Warren R.B., Waweru H., Weinman J., Griffiths C.E.M., Barker J.N., Smith C.H., Galloway J.B., Mahil S.K.. Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. BRITISH JOURNAL OF DERMATOLOGY. 2022; 187(2)DOI:10.1111/bjd.21042. PMID:35104366. IF:10.300(Q1/1D).

Zachariae C., Mrowietz U., Strodl Andersen J., Puig L.. Multistate modelling of probability of on-treatment clinical response and time remaining in response in patients with moderate-to-severe psoriasis treated with brodalumab or ustekinumab in the AMAGINE-2 and -3 studies. EUROPEAN JOURNAL OF DERMATOLOGY. 2022; 32(4)DOI:10.1684/ejd.2022.4304. PMID:36301758. IF:2.500(Q2/5D).

Sánchez-Rodríguez G., Puig L.. Leishmaniasis and anti-TNF drugs. Piel. 2022; 37(6)DOI:10.1016/j.piel.2021.06.020. PMID:. IF:(Q/D).

Van Huizen A.M., Menting S.P., Gyulai R., Iversen L., Van Der Kraaij G.E., Middelkamp-Hup M.A., Warren R.B., Spuls P.I., Schejtman A.A., Egeberg A., Firooz A., Kumar A.S., Oakley A., Foulkes A., Ramos A.M.C., Fougerousse A.-C., Carija A., Akman-Karakas A., Horváth B., Fábos B., Matlock B.H., Claréus B.W., Castro C., Ferrándiz C., Correa C.C., Marchesi C., Goujon C., Gonzalez C., Maldonado-García C., Hong C.-H., Griffiths C.E.M., Vestergaard C., Echeverría C.M., De La Cruz C., Conrad C., Törocsik D., Drvar D.L., Balak D., Jullien D., Appelen D., Kim D.H., De Jong E.M.G.J., El Gamal E., Laffitte E., Mahé E., Sonkoly E., Colombo E.P., Vilarrasa E., Willaert F., Novoa F.D., Handjani F., Valenzuela F., Vílchez-Márquez F., Gonzalez G.O., Krisztián G., Damiani G., Krnjevic-Pezic G., Pellerano G., Carretero G., Hunter H.J.A., Riad H., Oon H.H., Boonen H.P.J., Moussa I.O., García-Doval I., Csányi I., Brajac I., Turchin I., Grozdev I., Weinberg J.M., Nicolopoulos J., Wells J., Lambert J.L.W., Ingram J.R., Prinz J.C., De Souza Sittart J.A., Sanchez J.L., Hsiao J.P.-F., Castro-Ayarza J.R., Maul J.-T., Van Den Reek J.M.P.A., Trcko K., Barber K., Reich K., Gebauer K.A., Khobzei K., Maul L.V., Massari L.P., Fardet L., Le Cleach L., Misery L., Chandrashekar L., Muresanu L.I., Lecluse L., Skov L., Frez M.L., Babic L.T., Puig L., Gomez L.C., Ramam M., Dutil M., El-Sayed M.H., Olszewska M., Schram M.E., Franco M.D., Llamas-Velasco M., Gonçalo M., Velásquez-Lopera M.M., Abad M.E., De Oliveira M.D.F.S.P., Seyger M.M.B., Kaštelan M., Rademaker M., Sikora M., Lebwohl M., Wiseman M.C., Ferran M., Van Doorn M., Danespazhooh M., Bylaite-Bucinskiene M., Gooderham M.J., Polic M.V., De Rie M.A., Zheng M., Gómez-Flores M., Salleras I Redonnet M., Silverberg N.B., Doss N., Yawalkar N., Chosidow O., Zargari O., De La Cueva P., Fernandez-Peñas P., Cárdenas Rojas P.J., Gisondi P., Grewal P., Sator P., Luna P.C., Félix P.A.O., Varela P., Holló P., Cetkovska P., Calzavara-Pinton P., Ghislain P.-D., Araujo R.R., Romiti R., Kui R., Ceovic R., Vender R., Lafuente-Urrez R.F., Del-Río R., Gulin S.J., Handa S., Mahil S.K., Kolalapudi S.A., Marrón S.E., Azimi S.Z., Janmohamed S.R., Da Cruz Costa S.A., Choon S.E., Urbancek S., Ayanlowo O., Margasin S.M., Wong T.-W., Mälkönen T., Hurtová T., Reciné T.R., Huldt-Nystrøm T., Torres T., Liu T.-Y., Leonidze T., Sharma V.K., Weightman W., Gulliver W., Veldkamp W.. International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. JAMA Dermatology. 2022; 158(5)DOI:10.1001/jamadermatol.2022.0434. PMID:35353175. IF:10.900(Q1/1D).

Papp K.A., Thoning H., Gerdes S., Megna M., Brandi H., Jablonski Bernasconi M.Y., Yélamos O.. Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasis. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(7)DOI:10.1080/09546634.2022.2095330. PMID:35875991. IF:2.900(Q2/4D).

Puig L., Daudén E., Cuervas-Mons M., Novella C., Guisado C.. Persistence and effectiveness of guselkumab treatment in patients with moderate-to-severe plaque psoriasis in a non-interventional real-world setting: The SPRING study. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2025; 39DOI:10.1111/jdv.19403. PMID:37567861. IF:8.000(Q1/1D).

Armario-Hita JC, Carrascosa JM, Flórez Á, Herranz P, Pereyra-Rodríguez JJ, Serra-Baldrich E, Silvestre JF, Comellas M, Isidoro O, Ortiz de Frutos FJ. Pruritus and Pain Constitute the Main Negative Impact of Atopic Dermatitis From the Patient's Perspective: A Systematic Review. Dermatitis. 2024; 35(3)DOI:10.1089/derm.2023.0163. PMID:37751176. IF:3.200(Q1/2D).

Vilarrasa E, Camiña-Conforto G, Cabo F, Fernández-Vela J, Pousa M, Romaní J. Drainage setons for the management of sinus tracts in hidradenitis suppurativa.. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 2024; 90(5)DOI:10.1016/j.jaad.2023.08.058. PMID:37634739. IF:11.800(Q1/1D).

Mateu-Arrom, LL, Puig, LL. Choosing the right biologic treatment for moderate-to-severe plaque psoriasis: the impact of comorbidities. Expert Review of Clinical Pharmacology. 2024; 17(4)DOI:10.1080/17512433.2024.2340552. PMID:38603464. IF:3.000(Q2/4D).

Daudén, E, Escario, E, Martos-Cabrera, L, Armesto, S, Herrera-Acosta, E, Vidal, D, Vilarrasa, E, Rivera, R, de la Cueva, P, Martorell, A, Ballesca, F, Belinchón, I, Carretero, G, Rodríguez, L, Romero-Maté, A, Pujol-Montcusí, J, Salgado, L, Sahuquillo-Torralba, A, Coto-Segura, P, Baniandrés, O, Feltes, R, Riera-Monroig, J, Garrido, J, Llamas-Velasco, M. Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting. INTERNATIONAL JOURNAL OF DERMATOLOGY. 2024; 63(4)DOI:10.1111/ijd.16915. PMID:38168847. IF:3.200(Q1/3D).

Martí NR, Vilarrasa E, Llunell CL, Gamissans M, Sin M, Romaní J. Gluteal hidradenitis suppurativa: analysis of 83 patients [Hidradenitis supurativa con afectación glútea: análisis de 83 pacientes]. Actas Dermo-Sifiliograficas. 2024; 115(2)DOI:10.1016/j.ad.2023.09.021. PMID:37797882. IF:(Q/D).